Biota Holdings Limited is an Australian company engaged in anti-infective drug discovery and development, and its commercialization, with key capabilities in respiratory diseases, particularly influenza. Biota has developed the in-class neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza. Relenza is used to treat seasonal influenza. Biotaâ€™s research outcomes have included nucleoside analogues designed to treat hepatitis C virus (HCV) infections, licensed to Boehringer Ingelheim, and a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease. Biota has clinical trials underway with its lead compound for human rhinovirus (HRV) infection in patients with compromised respiration or immune systems. In addition, the Company has a partnership with Daiichi Sankyo for the development of second-generation influenza anti-virals. In March 2010, the Company completed acquisition of the antibacterial assets of MaxThera Inc.

Recent Milestones
edit

Biota Holdings received $423k in Venture Round funding. (4/27/10)

Posted 7/6/10 at 5:56pm
Biota Holdings acquired MaxThera for $1.5M. (11/12/09)

Posted 1/20/10 at 5:36am via com.au
Went public with stock symbol ASX:BTA.

Posted 7/6/10 at 5:51pm
Biota Holdings added Peter C. Cook as CEO, MD, Executive Director.

Posted 7/6/10 at 5:50pm
Biota Holdings added Damian T. Lismore as CFO.

Posted 7/6/10 at 5:50pm